Sudocrem boss: new skin drug will net €1.5bn - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Sudocrem boss: new skin drug will net €1.5bn

Home
Amryt Pharma
Sudocrem boss: new skin drug will net €1.5bn

Recent News

Open Orphan co-founder Carol Dalton on how a timely deal turned a pandemic into an opportunity
Open Orphan subsidiary develops human study for malaria
Surprise! Pfizer jumps the queue and leaps into RSV vax contention as COVID helps turbocharge work
The Executive Chairman of Open Orphan plc (LON:ORPH), Cathal Friel, Just Bought 2.5% More Shares
BRIEF—COVID-19 human challenge study to expand
Open Orphan launches infectious disease spinout

10 April 2016

Sudocrem boss: new skin drug will net €1.5bn 10 April 2016 online article

Prev
Next

Join us for our newsletters

Raglan Capital
4th Floor,
Fitzwilliam Hall,
Fitzwilliam Place,
Dublin 2
D02 T292
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
4th Floor,
Fitzwilliam Hall,
Fitzwilliam Place,
Dublin 2
D02 T292
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2022 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences